Acute Limb Ischemia (ALI) A Market of Multiple Therapies and Multiple Procedures
Acute limb ischemia (ALI) is defined as a sudden decrease or worsening of limb perfusion that threatens life and limb. ALI is usually defined as onset of 14 days or less.
This report estimates the U.S. incidence of acute limb ischemia (ALI) in patients and limbs, as well as incidence by cause, thrombosis and embolism.
ALI incidence is comprised of the annual number of ALI cases occurring in peripheral artery disease (PAD) and atrial fibrillation (AF) patients for 2015-2030.
The numbers of PAD patients and limbs are estimated according to the Diabetes Method. The annual occurrence of ALI in PAD patients is based on the results of a review of the published literature. The number of AF patients are derived from the literature as is the incidence of embolization in the lower limbs due to AF. Other populations which experience thromboembolic events are reviewed.
The market for treatment of ALI is estimated based on our assumption of the percentage of patients diagnosed and treated. Market estimates for 2015-2030 include ALI patients by cause (thrombosis or embolism) and the market in number of limbs. Market estimates are further detailed by SVS-ISVS Clinical Category and the number of patients requiring multiple therapies for ALI by cause (thrombosis or embolism), as well as the market for primary and revision therapies.